MicroQuin

MicroQuin is a biotechnology company founded by Dr. Scott Robinson and Yang Zheng, dedicated to developing innovative therapeutics for challenging diseases, with an initial emphasis on cancer treatment. The company has created a targeted delivery platform for chemotherapy that selectively directs therapeutic agents to cancer cells, minimizing harm to healthy cells and tissues. This approach involves binding to the cell surface of cancer cells, destroying the endoplasmic reticulum, lysing intracellular organelles, and promoting cell death signals exclusively in malignant cells. MicroQuin's advancements aim to enhance the efficacy of existing chemotherapeutic drugs used for various cancers, including breast, lung, prostate, ovarian, and melanoma. The company, recognized as a 2018 MassChallenge Finalist and a recipient of the CASIS/Boeing Prize for research on the International Space Station, is headquartered at LabCentral in Cambridge, Massachusetts.